A Study of ONO-7475 in Patients With Acute Leukemias
Status:
Recruiting
Trial end date:
2023-02-21
Target enrollment:
Participant gender:
Summary
[Updated]: To assess the safety and tolerability of ONO-7475 monotherapy in patients with
relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic
syndromes and to assess: i) safety and tolerability and ii) preliminary efficacy of the
combination of ONO-7475 and venetoclax in patients with relapsed or refractory acute myeloid
leukemia.